• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Anti-SARS-CoV-2 Recombinant Nanobodies

Nanobodies against the Receptor-binding domain of SARS-CoV-2 Spike protein

Nanobodies, often also called VHHs, are alternatives to conventional IgG antibodies and are characterized by their small single domains. Proteintech’s Nanobodies against SARS-CoV-2 are characterized by their strong neutralization efficacy, unique epitopes, small size, high stability and solubility, and fast tissue penetration. These small neutralizing affinity reagents offer an attractive addition to the SARS-CoV-2 IgGs in our portfolio.

Twelve novel Nanobody clones against the Receptor-binding domain (RBD) of SARS-CoV-2 Spike protein

In addition to our IgG antibodies against the Spike protein of SARS CoV-2, we now offer our ChromoTek range of twelve novel anti-SARS-CoV-2 Nanobodies directed against the Receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein. The Nanobody clones are either monovalent [#sc-NM1220 – sc-NM1230] for single-epitope binding or bi-paratopic [#sc-NM1266 & sc-NM-1267] for higher affinity binding due to avidity. All twelve Nanobody clones have unique epitopes, some of which target the RBD:ACE2 interface, while others bind to an epitope outside the interface.

Nanobody clone sc-NM1267 binds to emerging RBD variants of SARS-CoV-2

The bi-paratopic Nanobody clone sc-NM1267 binds to two distinct sites, one epitope inside and one outside of the RBD:ACE2 interface. Affinity analysis using Bio-Layer Interferometry (BLI) demonstrate that sc-NM1267 binds with the same affinity to RBD variants B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma), P3 (Theta), and A.23.1. Slightly decreased but still high binding affinities are observed for B.1.617.2 (Delta), B.1.429 (Epsilon), and B.1.617.1 (Kappa). In addition, sc-NM1267 shows strong neutralization SARS-CoV-2 wildtype and SARS-CoV-2 B.1.351 (Beta).

Benefits of Nanobodies in COVID-19 research:

  • Nanobodies bind unique, 3-dimensional conformations of epitopes not recognized by traditional anti-SARS-CoV-2 antibodies.
  • The small Nanobody size of 15 kDa enables binding of multiple Nanobodies against different epitopes on the same target.
  • Nanobodies can be easily used in multivalent or multi-paratopic formats which provide strong neutralizing efficacy ideal for therapeutic applications.
  • Due to the small size of Nanobodies they ensure faster and more efficient tissue penetration.
  • Nanobodies have a high solubility and chemical stability and a compact fold. They can be used in many different environments and even under harsh conditions.
  • The lack of an Fc moiety of Nanobodies prevents severe adverse events such as ADE and their low immunogenicity underlines the potential as advanced therapeutic tools.

The individual Nanobody clones are based on the research from Wagner et al. [DOI 10.15252/embr.202052325 and 10.1101/2021.08.08.455562].

Applications:

  • Neutralization assays
  • Competitive multiplex binding assays
  • Epitope mapping

SARS-CoV-2 Spike Recombinant Nanobodies

Product name Clone Applications Species reactivity
SARS-CoV-2 Spike Recombinant VHH [NM1220] NM1220 BLI, Multiplex ACE2 competition assay Virus
SARS-CoV-2 Spike Recombinant VHH [NM1221] NM1221 BLI, Multiplex ACE2 competition assay Virus
SARS-CoV-2 Spike Recombinant VHH [NM1222] NM1222 BLI, Multiplex ACE2 competition assay Virus
SARS-CoV-2 Spike Recombinant VHH [NM1223] NM1223 BLI, Multiplex ACE2 competition assay Virus
SARS-CoV-2 Spike Recombinant VHH [NM1224] NM1224 BLI, Multiplex ACE2 competition assay Virus
SARS-CoV-2 Spike Recombinant VHH [NM1226] NM1226 BLI, Multiplex ACE2 competition assay Virus
SARS-CoV-2 Spike Recombinant VHH [NM1227] NM1227 BLI, Multiplex ACE2 competition assay Virus
SARS-CoV-2 Spike Recombinant VHH [NM1228] NM1228 BLI, Multiplex ACE2 competition assay Virus
SARS-CoV-2 Spike Recombinant VHH [NM1229] NM1229 BLI, Multiplex ACE2 competition assay Virus
SARS-CoV-2 Spike Recombinant VHH [NM1230] NM1230 BLI, Multiplex ACE2 competition assay Virus
SARS-CoV-2 Spike Recombinant VHH [NM1266] NM1266 BLI, Multiplex ACE2 competition assay Virus
SARS-CoV-2 Spike Recombinant VHH [NM1267] NM1267 BLI, Multiplex ACE2 competition assay Virus

References:

NeutrobodyPlex—monitoring SARS-CoV-2 neutralizing immune responses using nanobodies

A broadly neutralizing biparatopic Nanobody protects mice from lethal challenge with SARS-CoV-2 variants of concern

 

Related content: